2 completed. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
Follow Recurrent Cervical Carcinoma: new trials by email Literature Review of Recurrent Cervical Carcinoma trials Research Report on Recurrent Cervical Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Bevacizumab, Cisplatin, Laboratory Biomarker Analysis - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 452 | 2009-04-01 | 2019-07-23 |
| Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Cisplatin, Gemcitabine Hydrochloride, Paclitaxel - Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma | Phase 3 | Completed | Gynecologic Oncology Group | 513 | 2003-05-01 | 2018-10-17 |
Uterine Cervical Neoplasms (2)
Female Urogenital Diseases (2) · Female Urogenital Diseases and Pregnancy Complications (2) · Genital Diseases (2) · Genital Diseases, Female (2) · Genital Neoplasms, Female (2) · Neoplasms (2) · Neoplasms by Site (2) · Urogenital Diseases (2) · Urogenital Neoplasms (2) · Uterine Cervical Diseases (2) · Uterine Diseases (2) · Uterine Neoplasms (2)
1,2-diaminocyclohexaneplatinum II citrate (2) · Cisplatin (2) · Paclitaxel (2) · Platinum (2) · Taxes (2) · Topotecan (2) · Bevacizumab (1) · Disulfides (1) · Gemcitabine (1) · Immunoglobulin G (1) · Vinorelbine (1)
Gynecologic Oncology Group (1) · National Cancer Institute (NCI) (1)
United States (2) · Spain (1)
Bradley Monk (1) · Krishnansu Tewari (1)
PMID 24552320, PMID 25638326, PMID 28756902, PMID 32847980, PMID 36898292
U10CA027469 (2), U10CA180868 (1)